Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Febuxostat (Uloric): Xanthine oxidase inhibitor approved for chronic management of hyperuricemia in patients with gout
Formulary , 03/06/09
Febuxostat is a xanthine oxidase inhibitor that decreases serum uric acid. This agent was approved on February 13, 2009, for the chronic management of hyperuricemia in patients with gout.
Today in Gout and Hyperuricemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Crystal-induced neutrophil activation
Immunology & Cell Biology, 12/09/09
Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease
PLoS ONE - Cardiovascular Disorders, 11/10/09
The modern management of gout
Rheumatology, 10/08/09
Sponsor
Article Search
Sponsor